Accelerate development of engineered iPSC-derived cell products with a RUO hiPSC line built for site-specific gene insertion using TARGATT™ technology.
The ActiCells™ GMP-Matching RUO TARGATT™ hiPSC Knock-in Kit (Cat.# AST-9450) gives you a powerful foundation for building engineered iPSC-derived cell products with high precision and biological relevance. Derived from neonatal CD34+ cord blood cells, these hiPSCs start with a lower mutational burden and broader developmental potential than adult somatic sources, making them a superior starting point for applications that require genomic stability and flexible lineage differentiation.
Pre-engineered with a TARGATT™ landing pad at the H11 safe harbor locus, the ActiCells™ GMP-Matching RUO TARGATT™ hiPSC Knock-in Kit enables site-specific, single-copy insertion of large DNA payloads—up to 20 kb (more with nested reactions)—with consistent and predictable expression. This targeted integration eliminates the variability, silencing, and safety concerns associated with random integration methods.
Learn more about the TARGATT™ platform and how it enhances cell line engineering>
Designed as the research-use-only (RUO) counterpart to our ActiCells™ GMP TARGATT hiPSC Knock-in Kit (Cat.# AST-9480), AST-9450 offers an isogenic path to clinical-grade materials, allowing you to optimize your payload designs and editing strategy with full confidence that your protocols will transfer to GMP. If you need a customized version of this line we offer full iPSC gene editing services to meet your specific needs.
The parental hiPSC line used for AST-9450 has been successfully differentiated into cardiomyocytes, natural killer (NK) cells, T cells, monocytes/macrophages, and endothelial cells—demonstrating its versatility across a range of lineages.
Each ActiCells™ GMP-Matching RUO TARGATT™ hiPSC Knock-in Kit contains sufficient cells and plasmids for 3 transfections and comes with:
As with all TARGATT™ technology-enabled products, this kit requires a license for commercial use and a materials transfer agreement (MTA) for academic use.
TARGATT™ large knock-in technology leverages a site-specific serine integrase to unidirectionally insert plasmid DNA sequences into the genome at the TARGATT™ landing pad—learn more by visiting the TARGATT™ Technology page.
ActiCells™ RUO TARGATT hiPSCs are pluripotent
ActiCells™ RUO TARGATT hiPSCs possess a normal karyotype
ActiCells™ RUO TARGATT hiPSCs differentiate to the three germ layers
ActiCells™ RUO TARGATT hiPSCs stably express an inserted transgene, red fluorescent protein (RFP)
Didn’t find all the info you were looking for?
Still have questions?
No problem.
No, the ActiCells™ GMP-Matching RUO TARGATT™ hiPSC Knock-in Kit is for research use only. We offer a matching GMP grade knock-in kit for clinical applications, the ActiCells™ GMP TARGATT™ hiPSC Knock-in Kit (Cat.# AST-9480).
The ActiCells™ RUO TARGATT™ iPSC Master Cell Line is engineered from our ActiCells™ GMP hiPSC Line (Cat.# ASE-9280), a well-characterized, karyotype-normal hiPSC line reprogrammed from CD34+ cord blood cells from a fully consented male donor.
TARGATT™ technology enables highly efficient, single-copy, site-specific integration at the H11 safe harbor locus. Integration is stable and results in long-term expression—advantages that other random or multi-copy insertion methods cannot consistently provide.
TARGATT™ technology provides high knock-in efficiency with stable and site-specific gene integration. After drug selection, efficiency can approach 90%.
The TARGATT™ system uses a patented serine integrase that specifically recognizes TARGATT™ attB sites in the cloning plasmid (also referred to as the donor plasmid) and attP sites in the TARGATT landing pad. Because unbound double strand breaks are not created, random integration using the host double strand break repair machinery does not occur.
TARGATT™ can efficiently insert payloads of 20 kb in a single reaction and larger payloads with nested TARGATT™ landing pads, making the technology suitable for a wide range of genetic engineering applications.
Yes, the TARGATT™ cloning plasmid allows you to clone and amplify your desired gene of interest for site-specific insertion.
Fill out the contact form below and a team member will be in touch within one business day.
